Prognostic role of early prostate specific antigen changes after [ 177 Lu ] Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis
European Journal of Clinical Investigation · 2023-09 · 53 (9)
DOI: 10.1111/eci.14014 ↗At a glance
Metaanalyse in European Journal of Clinical Investigation, 2023-09. Written by Luca Giovanella and 4 co-authors. Institution: Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland. Major MEDLINE topics: Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant. Cited 16 times so far (Crossref); 52 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Approximately 10%–20% of prostate cancers progress to metastatic and castration‐resistant forms (mCRPC). Radioligand (RLT) therapy with [ 177 Lu]Lu‐prostate‐specific membrane antigen (PSMA) is an emerging treatment for metastasized mCRPC and its efficacy is assessed not only but also by prostate specific antigen (PSA) measurement after 12 weeks or more after treatment. Our aim was to evaluate the role of early PSA measurement after RLT in predicting overall survival (OS) of mCRPC patients.
Methods
A systematic search on PubMed, Web Of Science and Scopus was performed from January to December 2022. PRISMA guidelines for prognostic studies was adopted. Risk of bias was assessed using quality of prognostic studies (QUIPS).
Results
Twelve studies at low‐intermediate risk of bias, were included in the meta‐analysis (1646 patients, mean age 70 years). About 50% of patients showed a PSA decline after 1–2 of [ 177 Lu]Lu‐PSMA, and more than 30% reported a PSA decline ≥50%. The median OS range for patients with any PSA decline was 13–20 months, while for patients with stable or increased PSA, the median OS fell to 6–12 months. The OS rate for a PSA decline after the one‐two [ 177 Lu]Lu‐PSMA cycles was 0.39 (95% CI: 0.31–0.50), while OS for a PSA decline ≥50% was 0.69 (95% CI: 0.57–0.83).
Conclusions
A PSA decline is observed in almost 50% of mCRPC patients after 1–2 [ 177 Lu]Lu‐PSMA cycles, with a significantly longer OS compared to stable or increased PSA levels, respectively. Accordingly, any PSA decline after 1–2 cycles of therapy should be regarded as a favourable prognostic factor for OS .
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
- Clinic for Nuclear Medicine, University Hospital of Zürich, Zürich, Switzerland.
- Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Research Unit of Cardiac Surgery, Department of Cardiovascular Surgery, Università Campus Bio-Medico, Rome, Italy.
- Clinic for Nuclear Medicine, Essen University Hospital, Essen, Germany.
ORCID profiles: Luca Giovanella, Maria Luisa Garo
Cite
APA
Giovanella, L., Garo, M. L., Cuzzocrea, M., Paone, G., & Herrmann, K. (2023). Prognostic role of early prostate specific antigen changes after [ 177 Lu ] Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14014
Vancouver
Giovanella L, Garo ML, Cuzzocrea M, Paone G, Herrmann K. Prognostic role of early prostate specific antigen changes after [ 177 Lu ] Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis. European Journal of Clinical Investigation. 2023. doi:10.1111/eci.14014
BibTeX
@article{Giovanella2023,
author = {Giovanella, Luca and Garo, Maria Luisa and Cuzzocrea, Marco and Paone, Gaetano and Herrmann, Ken},
title = {Prognostic role of early prostate specific antigen changes after [ 177 Lu ] Lu‐PSMA radioligand therapy of metastasized prostate cancer: A meta‐analysis},
journal = {European Journal of Clinical Investigation},
year = {2023},
doi = {10.1111/eci.14014}
}
EUVIMED